Tag: adalimumab

1. Adalimumab was efficacious when used simultaneously with wide-excision surgery for treatment of moderate to severe hidradenitis suppurativa (HS). Evidence Rating Level: 1 (Excellent) Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects the hair follicles, and is characterized by painful nodules, abscesses, scarring, and tissue destruction. It usually occurs...
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib was associated with more frequent adverse events than adalimumab. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriatic arthritis (PA) is an autoimmune condition primarily affecting the skin and joints. The condition is...
Epidemiology, Clinical Course, and Outcomes of Critically Ill Adults With COVID-19 In New York City: A Prospective Cohort Study 1. COVID-19-positive adults were commonly found to have at least one comorbid condition, including hypertension and diabetes. 2. In-hospital mortality was independently associated with older age, chronic cardiac and pulmonary diseases, and...
1. Carriage of the HLA-DQA1*05 allele is significantly associated with the development of antibodies against anti-TNF agents. Evidence Rating Level: 2 (Good) Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologics for treating immune-mediated diseases. However, repeated administration can lead to the formation of anti-drug antibodies (immunogenicity), which can...
In patients with Crohn’s disease (CD), endoscopic evidence of healing after treatment is associated with favorable outcomes. Anti-tumor necrosis factor (TNF) agents have been shown to induce ileocolonic healing in CD, however the impact of these agents on gross small bowel healing as indicated by endoscopy has not been...
In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously at weeks 0 and 4, or 80 mg of adalimumab subcutaneously, and then 40 mg at weeks 1, 3, 5 and every other week thereafter during a 16-week treatment...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...